Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice

Sandra B Haudek1, Ying Xia, Peter Huebener

  • 1DeBakey Heart Center, Baylor College of Medicine, Methodist Hospital, Houston, TX 77030, USA.

Insights

Serum amyloid P (SAP) prevents monocyte-derived fibroblasts and cardiac fibrosis in a mouse model of ischemia/reperfusion cardiomyopathy (I/RC). SAP administration blocked fibrosis without affecting inflammation, suggesting a role in regulating inflammation-fibrosis linkage.

Area of Science:

  • Cardiovascular Research
  • Fibrosis Mechanisms
  • Immunology

Background:

  • Ischemia/reperfusion cardiomyopathy (I/RC) involves prolonged monocyte chemoattractant protein 1 (MCP-1) elevation.
  • I/RC hearts exhibit proliferative spindle-shaped fibroblasts expressing myofibroblast, precursor, and hematopoietic markers.

Purpose of the Study:

  • To investigate the origin and therapeutic targeting of fibroblasts in I/RC.
  • To explore the role of serum amyloid P (SAP) in modulating I/RC-induced cardiac remodeling.

Main Methods:

  • Created chimeric mice by bone marrow transplantation to trace fibroblast origin.
  • Administered SAP in vivo to I/RC mouse models.
  • Assessed cardiac fibrosis, ventricular dysfunction, inflammation, and chemokine expression.

Main Results:

  • Fibroblasts in I/RC hearts were confirmed to be of bone marrow origin.
  • SAP administration significantly reduced proliferative fibroblasts and completely prevented I/RC-induced fibrosis and ventricular dysfunction.
  • SAP did not suppress inflammation or chemokine expression in I/RC hearts.

Conclusions:

  • SAP interferes with monocyte differentiation into fibroblasts, offering a potential therapeutic strategy for I/RC.
  • SAP may be a key regulator linking cardiac inflammation and nonadaptive fibrosis.